Patients with COVID-19 received less frequently IV tissue-type plasminogen activator (tPA) (4.5 [1/22] vs. 64.7% [11/17], p < 0.001) or mechanical thrombectomy (22.7 [5/22] vs. 64.7% [11/17], p = 0.008) with longer median time intervals from stroke onset to endovascular treatment (581 vs. 265 min., p = 0.036) (Table 1). The gene discussed is PLAT; the disease is Stroke.